Kronos blames enrollment troubles for ending phase 3 AML program
10 Nov 2022 //
FIERCEBIOTECH
Kronos Bio and Invivoscribe Partner for Use with Entospletinib
16 Aug 2022 //
PRNEWSWIRE
Kronos Bio`s SYK Inhibitors Entospletinib and Lanraplenib at EHA 2022
12 May 2022 //
GLOBENEWSWIRE